Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers
Incorporating molecular markers into RMS prognosis models improves prognosis predictions. Individualized prognosis predictions may suggest alternative treatment regimens compared with traditional risk-classification schemas. Improved clinical variables and external validation are required before implementing these models into clinical practice.
Authors
- Mark Zobeck (ORCID: https://orcid.org/0000-0003-0997-906X)
- Michael E. Scheurer (ORCID: https://orcid.org/0000-0002-8379-6088)
- Javed Khan (ORCID: https://orcid.org/0000-0002-5858-0488)
- M. Fatih Okcu (ORCID: https://orcid.org/0000-0001-9492-8675)
- Rajkumar Venkatramani (ORCID: https://orcid.org/0000-0002-4785-106X)
- Philip J. Lupo (ORCID: https://orcid.org/0000-0003-0978-5863)
Institutions
- Baylor College of Medicine (US)
- National Cancer Institute (US)
- Texas Children's Hospital (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1200/po-24-00556
- Citations
- 1
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Institutes of Health